UnitedHealthcare
erlotinib (erlotinib)
Drugs for Cancer : Drugs for Cancer
  • May be covered under Medical Benefit.
  • Diabetes Type 2: Long Acting Insulin + Combo:
    Duration: 1 plan year
    Documented Diagnosis: Yes
    Medical Test Required: No
    Reauthorization Required: Yes
    Duration of Reauthorization: = 1 plan year
    Supporting Documentation Requirements: 2 of Chart Notes;Medication History

  • Quantity Limit: 1 spacer per prescription
  • Quantity Limit: limit maximum 1 GM PER 30 day(s)